Cite
HARVARD Citation
Ye, B. et al. (2019). Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 393 (10182), pp. 1699-1707. [Online].